Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03588936 · ClinicalTrials.gov registry record · Phase 1
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03588936 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 2 participants.
The verdict
NCT03588936, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.
Interventions
- DRUG Tocilizumab
- DRUG Nivolumab (.25 mg/kg)
- DRUG Nivolumab (.5 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03588936
The ClinicalTrials.gov registry entry for NCT03588936 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tocilizumab is the first listed.
NCT03588936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03588936 about?
NCT03588936 is a clinical study titled "Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant". This is a phase 1, interventional single arm, open label, treatment study designed to evaluate the safety combination programmed cell death protein 1 (PD-1) and interleukin 6 (IL-6) inhibition in participants with relapsed disease post-allogeneic transplant.
What is the current status of trial NCT03588936?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2018-09-14. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03588936?
The interventions under investigation include: Tocilizumab (DRUG), Nivolumab (.25 mg/kg) (DRUG), Nivolumab (.5 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT03588936?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.